Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ World https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Biden’s orphaned stocks of AstraZeneca increased to 20 million doses

Biden’s orphaned stocks of AstraZeneca increased to 20 million doses

US stocks of contradictory The AstraZeneca Plc coronavirus vaccine has risen to more than 20 million doses, according to sources, although the shot seems unlikely to take into account President Joe Biden’s internal vaccination campaign.

AstraZeneca has not yet sought permission from the Food and Drug Administration for the two-dose vaccine, and the company faces safety issues abroad and scrutiny by U.S. regulators, who have already reprimanded it for wrongdoing during clinical trials and partial data messages.

Three other vaccines, already approved in the United States, are entering American hands at a rate of about 3 million doses a day, with hundreds of millions of additional doses to be delivered by August.

This raises the question for Biden: What to do with the AstraZeneca vaccine? The company already has more than 20 million doses, part of a total of between 80 and 90 million at some stage of custom production in the United States, people familiar with the matter said. U.S. allies have already sought doses from U.S. stockpiles of AstraZeneca, and the cheaper vaccine could inoculate people in dozens of low-income countries who can̵

7;t afford vaccinations from And Modern Inc.

Read more: AstraZeneca’s Dramatic risks of vaccines prolonging the pandemic

“Give them all. Until we even think about resolving it, we will be oversaturated in the country, “said Zeke Emmanuel, a physician and vice protestant at the University of Pennsylvania who was a senior health policy adviser in the Obama administration and Biden’s Covid Transition Advisory Board.

“We will never use them,” he said.

Celine Gounder, a doctor who also served on Covid’s Biden transition advisory board, agreed that the doses should be donated once the company has received FDA approval. “We have enough – we don’t even need it Johnson & Johnson, “said the third authorized manufacturer in the United States.

“I would like to see the FDA continue its process, issue an emergency use permit if it accepts it passes, and then donate it,” she added.

FDA approval is “really important,” she said, “because of all the different issues with the AstraZeneca vaccine.”

Coagulation Association

Earlier this week, the European Union’s regulatory body said it had found a “strong link” between AstraZeneca shots and rare blood clots, especially in younger patients. UK regulators have said that people under the age of 30 should be offered an alternative vaccine, if any.

More than 726 million photos are given: Covid-19 Tracking

This was followed by an unusual rebuke from US regulators in March, who accused the company of publishing “potentially misleading” data from a large clinical trial in the United States. AstraZeneca revised the vaccine efficacy evaluations slightly downwards.

AstraZeneca is now looking for a new production of the vaccine’s active ingredient in the United States after agreeing to release a concerned Emergent Biosolutions Inc. plant in Baltimore, who confused the production of his photo with Johnson & Johnson’s. The Biden administration mediated the acquisition of the plant by J&J.

The United States is set to receive enough vaccines for its entire adult population by the end of next month, with another 200 million doses arriving from Modern and Pfizer by the end of July. White House officials said they wanted an overdose in part to vaccinate children once the dose was approved for people under 16. Given the problems with younger adults, it is unclear whether the AstraZeneca shot will ever be approved for use by American youth.

The administration is not making any decisions regarding AstraZeneca until the FDA completes its review, said an official familiar with the matter, who, like other officials, was given anonymity to discuss the matter.

Last year, the US government spent $ 1.2 billion to accelerate the research, development, production and delivery of 300 million doses of AstraZeneca vaccine. At the time, the Trump administration’s health and social services ministry said it expected the first doses to be delivered in October last year.

Source link